Port Ranibizumab Delivery Effective in Neovascular AMD

A port delivery system of ranibizumab (Lucentis, Genentech) is effective in neovascular age-related macular degeneration. Data from the phase 3 Archway trial showed efficacy of 100 mg/mL ranibizumab administered via port every 24 weeks was noninferior to monthly intravitreal ranibizumab injections.

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ